Objective: A survey was implemented for early assessment of pandemic-related practice processes and quality improvement (QI). Background: In response to the public health measures in Hawaii to curtail the coronavirus 2019 pandemic, Hawaii Pacific Neuroscience (HPN) adapted their patient care to ensure continuity of neurological treatment. Methods: The telephone survey was conducted on patients seen at HPN during the period of April 22, 2020-May 18, 2020 to address four areas related to patients' outpatient experience: delivery of care, general well-being, experience with telemedicine, and disease-specific questions. Dr. Patricia Borman for their contributions to the survey.

No abstract

Dementia, especially Alzheimer's disease, is an important cause of seizures and epilepsy midst the elderly. With the increasing life span, the incidence of dementia and epilepsy is expected to increase exponentially. Care of patients with advanced dementia can be demanding and seizures add to this burden. Though recognition of seizures in these patients can be difficult, seizures in these patients tend to be highly responsive to pharmacological therapy. However, choosing the right antiepileptic drug can be a challenge and complicated by altered kinetics and polypharmacy. While ongoing seizures can worsen the cognitive status in these patients, antiepileptic drugs could also add to the cognitive burden. The newer generation drugs show promise in terms of their side effect profile without compromising on the efficacy.